The effect of long‐term untreated growth hormone deficiency (GHD) and 9 years of GH replacement on the quality of life (QoL) of GH‐deficient adults

Gilchrist, Francis J; Murray, Robert; Shalet, Stephen M

doi:10.1046/j.1365-2265.2002.01608.x

Cited by 80 publications

(63 citation statements)

References 26 publications

(40 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Using the AGHDA, they found significant improvements in wellbeing from 3 months. Gilchrist et al (32) report that improvements in QOL are maintained for up to 9 years in patients who choose to continue GH therapy after a trial. In contrast, Whitehead et al (33) found no improvement in NHP or PGWB scores in their 6-month, double-blind placebo-controlled trial of 'high dose' GH therapy.…”

Section: Discussionmentioning

confidence: 99%

Atypical depression in growth hormone deficient adults, and the beneficial effects of growth hormone treatment on depression and quality of life

Mahajan

Crown²,

Checkley³

et al. 2004

European Journal of Endocrinology

View full text Add to dashboard Cite

Objective: Some growth hormone deficient adults (GHDAs) have an impaired quality of life, which may improve with growth hormone (GH) treatment. The objective of our study was to make an in-depth psychiatric evaluation of patients with adult-onset (AO) and childhood-onset (CO) GH deficiency (GHD), and to assess the time course of changes in their quality of life and symptoms of depression in response to GH treatment. Design: The study design was a 4-month, double-blind, cross-over, placebo-controlled trial of GH therapy. Methods: We used a detailed psychiatric interview to characterise 25 patients with proven GHD at baseline. They were reassessed at monthly intervals during treatment with GH or placebo, using the Nottingham Health Profile and two well-recognised depression rating scales. Results: 11/18 (61%) of the patients with AO-GHD, but 0/7 of the patients with CO-GHD, were found to have atypical depression at baseline. There were significant improvements in the depression rating scale scores after 2 months of GH therapy, with significant improvements in emotional reaction and social isolation scores from 1 month, and in energy levels and sleep disturbance from 2 and 3 months respectively. Conclusions:The results of our study confirm that a large proportion of GHDAs have unequivocal psychiatric morbidity, and suggest that a response to treatment can be seen after a short trial of GH therapy. We hypothesise that this rapid improvement of symptoms of atypical depression represents a direct central effect of GH therapy.European Journal of Endocrinology 151 325-332

show abstract

Section: Discussionmentioning

confidence: 99%

Atypical depression in growth hormone deficient adults, and the beneficial effects of growth hormone treatment on depression and quality of life

Mahajan

Crown²,

Checkley³

et al. 2004

European Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…GH exerts well-defined effects on body composition, bone, cardiovascular function, metabolism, pulmonary function, and skin that may impact QoL. Indeed, GH-induced improvements in the physical mobility (Attanasio et al 1997, Gilchrist et al 2002 and energy (Wallymahmed et al 1997) subsections of QoL indices would likely be mediated at somatic sites. The relevance of somatic actions of GH to QoL is not, however, accepted by all investigators (Barkan et al 2000).…”

Section: Therapeutic Mechanisms: Somatic Effectsmentioning

confidence: 99%

Growth hormone therapy and Quality of Life: possibilities, pitfalls and mechanisms

Hull

Harvey²

2003

Journal of Endocrinology

View full text Add to dashboard Cite

The actions of growth hormone (GH) are not restricted to growth: GH modulates metabolic pathways as well as neural, reproductive, immune, cardiovascular, and pulmonary physiology. The importance of GH in most physiological systems suggests that GH deficiency at any age would be associated with significant morbidity. However, prior to the advent of recombinant GH, cadaverderived GH was only used therapeutically to correct the height deficit, and thereby hypothetically improve quality of life (QoL), in GH-deficient children. Physicians now have access to unlimited, albeit expensive, supplies of recombinant GH, and are considering the advisability of GH replacement or supplementation in other patient populations. This paper analyses studies investigating the relationship between GH and QoL in GH-deficient children or adults, in GH-replete short children suffering from idiopathic short stature, Turner syndrome, or intrauterine growth retardation and in GH-deficient or replete elderly adults. Possible mechanisms by which GH might improve QoL at neural and somatic sites are also proposed.

show abstract

“…SF-36 component summary scores were compared between baseline and post-treatment (after 12 months) using Wilcoxon signed-rank test. Correlations more apparent) with long-term GH replacement therapy [10][11][12][13][14][15]. Interestingly, the findings of a retrospective survey study reported by Wiren et al [16] indicated that almost one-third of patients who ultimately experienced improvement in QOL did not notice this improvement until after 6 months of treatment.…”

Section: Discussionmentioning

confidence: 89%

Possible predictors for QOL improvement following GH replacement therapy in adult GHD

et al. 2015

View full text Add to dashboard Cite

ADULT GH DEFICIENCY (GHD) manifests as a clinical syndrome that is characterized by a number of abnormal physical and metabolic changes, including changes in body composition, lipid and carbohydrate metabolic profiles, bone mineral density, cardiac function, muscle strength, and aerobic capacity [1]. In addition, GHD can have a negative impact on cognitive function and quality of life (QOL) [1,2], particularly in adults with adult-onset (AO) GHD [3,4] Abstract. In addition to impaired physical activity, adult GH deficiency (GHD) can decrease quality of life (QOL). Hence, assessment of QOL is important to evaluate the efficacy of GH replacement therapy. This study aimed to identify factors that may be predictive of long-term improvement in QOL among clinical/laboratory variables during GH replacement therapy

show abstract

The effect of long‐term untreated growth hormone deficiency (GHD) and 9 years of GH replacement on the quality of life (QoL) of GH‐deficient adults

Cited by 80 publications

References 26 publications

Atypical depression in growth hormone deficient adults, and the beneficial effects of growth hormone treatment on depression and quality of life

Atypical depression in growth hormone deficient adults, and the beneficial effects of growth hormone treatment on depression and quality of life

Growth hormone therapy and Quality of Life: possibilities, pitfalls and mechanisms

Possible predictors for QOL improvement following GH replacement therapy in adult GHD

Contact Info

Product

Resources

About